Peptides and Therapeutic Proteins: New Opportunities for Macromolecule Development, Delivery, and Commercialization
Posted on: Wednesday, 13 July 2005, 09:00 CDT
NEW YORK, July 13 /PRNewswire/ -- Strategic Research Institute is pleased to announce the upcoming Peptides and Therapeutic Proteins: New Opportunities for Macromolecule Development, Delivery, and Commercialization is scheduled to take place on November 17-18, 2005 in Philadelphia, PA. The conference features presenters from industry and academic leaders on how proteins and peptides are becoming more therapeutically viable as new technologies, delivery systems, and R & D advances are all converging to make macromolecules more commercially attractive for the pharmaceutical industry.
The early 2000s have seen a spate of new medicines, such as monoclonal antibodies, whose success has been made possible through research and technology advances, especially in delivery systems.
The conference features over 30 speakers from pharma, specialty pharma, and biotech companies. The conference sections are: 1) Emerging Opportunities in Peptides, 2) Advances in Biotherapeutics & 3) New Technologies to Deliver Peptides, Proteins and Antibodies.
Protein and peptide therapeutics have been touted as a promising new addition to the pharmaceutical armamentarium over the last 10 to 20 years, but it is only recently that the field has caught fire.
New delivery techniques and manufacturing technologies, however, coupled with intensified research and development programs, resulted in the approval of new peptide-based drugs such as Fuzeon for HIV and Enbrel for RA, plus dozens of others. More importantly, there are 600 to 700 proteins peptides in development worldwide, and in 2004, the worldwide market was estimated to be about $1.1 billion. The United States makes up 65% of the total world market, followed by Europe at 30%.
Amylin, Roche, Schering Plough, Wyeth, Biogen Idec, Amgen, Genentech, and Eli Lilly & Co. are among the companies introducing new therapeutics to the market -- a second wave of revolutionary new drugs and are about to be introduced as many are completing Phase III Trials and will be approved shortly.
Call for speakers: Please contact Mark Alexay at malexay@srinstitute.com or 212-967-0095, extension 251, the organizer, to submit abstracts for consideration. The deadline is July 15, 2005. Abstracts should be titled and 50-100 words and include full contact information.
Strategic Research Institute
CONTACT: Mark Alexay of Strategic Research Institute, +1-212-967-0095,extension 251, malexay@srinstitute.com
Web site: http://www.srinstitute.com/
Source: PRNewswire
Related Articles
- Midwest Research Institute Selected to Help Companies Advance the Development of Influenza Vaccines
- Bentley Appoints David C. Brush to Lead Business Development and Strategic Planning
- Cytokinetics to Present at the 2006 RBC Capital Markets Healthcare Conference
- CollaGenex Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference
- Identify the Key & Niche Companies Operating in the World's Advanced Electronic Packaging Market
- Rigel Announces Pfizer Selection of R343, a Syk Kinase Inhibitor, for Advanced Preclinical Development in Allergic Asthma
- Unilever to Further Demonstrate Vitality at Annual Food Marketing Institute Conference and Expo; New Products and Innovative Research to Be Featured
- Achieving 5 G/L and Beyond Covered at IBC's Cell Line Development and Engineering Conference
- Experienced Scientific Researcher Joins Advaxis to Advance Development of Cancer Vaccines
- HistoRx, Inc. Moves to Advance the Development and Commercialization of New Quantitative Tissue Based Diagnostic Tests; Three Industry Leaders Bring New Level of Expertise to Emerging Molecular Diagnostics Company
 |
 |
User Comments (0)
RSS Feeds